Eryseng Parvo

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
13-05-2019
Summary of Product characteristics Summary of Product characteristics (SPC)
13-05-2019
Public Assessment Report Public Assessment Report (PAR)
03-10-2014

Active ingredient:

prašičev parvovirus, sev NADL-2 in Erysipelothrix rhusiopathiae, sev R32E11 (inaktiviran)

Available from:

Laboratorios Hipra, S.A.

ATC code:

QI09AL01

INN (International Name):

Porcine parvovirus and Erysipelothrix rhusiopathiae

Therapeutic group:

Prašiči

Therapeutic area:

Immunologicals for suidae, Inactivated viral and inactivated bacterial vaccines

Therapeutic indications:

Za aktivno imunizacijo ženskih prašičev za zaščito potomcev pred transplacentalno okužbo, ki jo povzroča prašičji parvovirus. Za aktivno imunizacijo moških in ženskih prašičev za zmanjšanje kliničnih znakov (poškodbe na koži in zvišana telesna temperatura), prašičje erysipelas, ki jih povzročajo Erysipelothrix rhusiopathiae, serotip 1 in 2 serotip.

Product summary:

Revision: 5

Authorization status:

Pooblaščeni

Authorization date:

2014-07-08

Patient Information leaflet

                                14
B. NAVODILO ZA UPORABO
15
NAVODILO ZA UPORABO
ERYSENG PARVO SUSPENZIJA ZA INJICIRANJE ZA PRAŠIČE
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ, ČE STA
RAZLIČNA
Imetnik dovoljenja za promet z zdravilom in izdelovalec odgovoren za
sproščanje serij:
LABORATORIOS HIPRA, S.A.
Avda. la Selva, 135
17170 Amer (Girona)
Španija
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
ERYSENG PARVO suspenzija za injiciranje za prašiče
3.
NAVEDBA UČINKOVIN(E) IN DRUGE(IH) SESTAVIN
Vsak 2-mililitrski odmerek vsebuje:
inaktiviran prašičji parvovirus, sev NADL-2
.......................................................... RP > 1,15*
inaktivirana bakterija
_Erysipelothrix rhusiopathiae_
, sev R32E11,…ELISA > 3,34 log
2
IE
50 %
**
*RP = relativna potenca (ELISA)
**
IE
50 %
- inhibicija ELISA 50%
aluminijev hidroksid
.............................................................................................
5,29 mg (aluminij)
DEAE-dekstran
korenina pravega ženšena (ginsenga)
Belkasta suspenzija za injiciranje.
4.
INDIKACIJA(E)
Za aktivno imunizacijo plemenskih svinj za zaščito potomstva pred
transplacentarno okužbo, ki jo
povzroča prašičji parvovirus.
Za aktivno imunizacijo merjascev in plemenskih svinj za zmanjšanje
kliničnih znakov (kožnih lezij in
vročine) rdečice, ki jo povzroča bakterija
_Erysipelothrix rhusiopathiae_
, serotip 1 in serotip 2.
Nastop imunosti:
Prašičji parvovirus: od začetka brejosti.
_E. rhusiopathiae_
: tri tedne po zaključku osnovne sheme cepljenja.
Trajanje imunosti:
Prašičji parvovirus: cepljenje zagotavlja zaščito ploda v času
trajanja brejosti. Revakcinacijo je treba
izvesti pred vsako brejostjo, glejte poglavje »Odmerki za posamezne
živalske vrste ter pot(i) in način
uporabe zdravila« .
_E. rhusiopathiae_
: cepljenje varuje pred rdečico do takrat, ko je priporočena
revakcinacija (približno
šest mesecev po osnovni shemi cepljenja), glejte poglavje »Odmerki
za posamezne živalske vrste ter

                                
                                Read the complete document

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
ERYSENG PARVO suspenzija za injiciranje za prašiče
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Vsak 2-mililitrski odmerek vsebuje:
UČINKOVINE:
inaktiviran prašičji parvovirus, sev NADL-2
.......................................................... RP > 1,15*
inaktivirana bakterija
_Erysipelothrix rhusiopathiae_
, sev R32E11,…ELISA > 3,34 log
2
IE
50 %
**
*RP - relativna potenca (ELISA)
**
IE
50 %
- inhibicija ELISA 50%
DDODATKI:
aluminijev hidroksid …………………….
................................................... 5,29 mg (aluminij)
DEAE-dekstran
korenina pravega ženšena (ginsenga)
Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Suspenzija za injiciranje
Suspenzija belkaste barve
4.
KLINIČNI PODATKI
4.1
CILJNE ŽIVALSKE VRSTE
Prašiči
4.2
INDIKACIJE ZA UPORABO PRI CILJNIH ŽIVALSKIH VRSTAH
Za aktivno imunizacijo plemenskih svinj za zaščito potomstva pred
transplacentarno okužbo, ki jo
povzroča prašičji parvovirus.
Za aktivno imunizacijo merjascev in plemenskih svinj za zmanjšanje
kliničnih znakov (kožnih lezij in
vročine) rdečice, ki jo povzroča bakterija
_Erysipelothrix rhusiopathiae_
, serotip 1 in serotip 2.
Nastop imunosti:
Prašičji parvovirus: od začetka brejosti.
_E. rhusiopathiae_
: tri tedne po zaključku osnovne sheme cepljenja.
Trajanje imunosti:
Prašičji parvovirus: cepljenje zagotavlja zaščito ploda v času
trajanja brejosti. Revakcinacijo je treba
izvesti pred vsako brejostjo, glejte poglavje 4.9.
_E. rhusiopathiae_
: cepljenje varuje pred rdečico do takrat, ko je priporočena
revakcinacija (približno
šest mesecev po osnovni shemi cepljenja), glejte poglavje 4.9.
3
4.3
KONTRAINDIKACIJE
Ne uporabite v primeru preobčutljivosti na zdravilne učinkovine, na
dodatke ali na katero koli
pomožno snov.
4.4.
POSEBNA OPOZORILA ZA VSAKO CILJNO ŽIVALSKO VRSTO
Cepite samo zdrave živali.
4.5
POSEBNI PREVIDNOSTNI UKREPI
Posebni previdnostni ukr
                                
                                Read the complete document

Similar products

Active ingredient prašičev parvovirus, sev NADL-2 in Erysipelothrix rhusiopathiae, sev R32E11 (inaktiviran)

prašičev parvovirus, sev NADL-2 in Erysipelothrix rhusiopathiae, sev R32E11 (inaktiviran)

ATC code QI09AL01

QI09AL01

Marketed by Laboratorios Hipra, S.A.

Laboratorios Hipra, S.A.

INN (International Name) Porcine parvovirus and Erysipelothrix rhusiopathiae

Porcine parvovirus and Erysipelothrix rhusiopathiae

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Bulgarian 13-05-2019
Public Assessment Report Public Assessment Report Bulgarian 03-10-2014
Patient Information leaflet Patient Information leaflet Spanish 13-05-2019
Summary of Product characteristics Summary of Product characteristics Spanish 13-05-2019
Public Assessment Report Public Assessment Report Spanish 03-10-2014
Patient Information leaflet Patient Information leaflet Czech 13-05-2019
Summary of Product characteristics Summary of Product characteristics Czech 13-05-2019
Public Assessment Report Public Assessment Report Czech 03-10-2014
Patient Information leaflet Patient Information leaflet Danish 13-05-2019
Summary of Product characteristics Summary of Product characteristics Danish 13-05-2019
Public Assessment Report Public Assessment Report Danish 03-10-2014
Patient Information leaflet Patient Information leaflet German 13-05-2019
Summary of Product characteristics Summary of Product characteristics German 13-05-2019
Public Assessment Report Public Assessment Report German 03-10-2014
Patient Information leaflet Patient Information leaflet Estonian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Estonian 13-05-2019
Public Assessment Report Public Assessment Report Estonian 03-10-2014
Patient Information leaflet Patient Information leaflet Greek 13-05-2019
Summary of Product characteristics Summary of Product characteristics Greek 13-05-2019
Public Assessment Report Public Assessment Report Greek 03-10-2014
Patient Information leaflet Patient Information leaflet English 13-05-2019
Summary of Product characteristics Summary of Product characteristics English 13-05-2019
Public Assessment Report Public Assessment Report English 03-10-2014
Patient Information leaflet Patient Information leaflet French 13-05-2019
Summary of Product characteristics Summary of Product characteristics French 13-05-2019
Public Assessment Report Public Assessment Report French 03-10-2014
Patient Information leaflet Patient Information leaflet Italian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Italian 13-05-2019
Public Assessment Report Public Assessment Report Italian 03-10-2014
Patient Information leaflet Patient Information leaflet Latvian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Latvian 13-05-2019
Public Assessment Report Public Assessment Report Latvian 03-10-2014
Patient Information leaflet Patient Information leaflet Lithuanian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Lithuanian 13-05-2019
Public Assessment Report Public Assessment Report Lithuanian 03-10-2014
Patient Information leaflet Patient Information leaflet Hungarian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Hungarian 13-05-2019
Public Assessment Report Public Assessment Report Hungarian 03-10-2014
Patient Information leaflet Patient Information leaflet Maltese 13-05-2019
Summary of Product characteristics Summary of Product characteristics Maltese 13-05-2019
Public Assessment Report Public Assessment Report Maltese 03-10-2014
Patient Information leaflet Patient Information leaflet Dutch 13-05-2019
Summary of Product characteristics Summary of Product characteristics Dutch 13-05-2019
Public Assessment Report Public Assessment Report Dutch 03-10-2014
Patient Information leaflet Patient Information leaflet Polish 13-05-2019
Summary of Product characteristics Summary of Product characteristics Polish 13-05-2019
Public Assessment Report Public Assessment Report Polish 03-10-2014
Patient Information leaflet Patient Information leaflet Portuguese 13-05-2019
Summary of Product characteristics Summary of Product characteristics Portuguese 13-05-2019
Public Assessment Report Public Assessment Report Portuguese 03-10-2014
Patient Information leaflet Patient Information leaflet Romanian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Romanian 13-05-2019
Public Assessment Report Public Assessment Report Romanian 03-10-2014
Patient Information leaflet Patient Information leaflet Slovak 13-05-2019
Summary of Product characteristics Summary of Product characteristics Slovak 13-05-2019
Public Assessment Report Public Assessment Report Slovak 03-10-2014
Patient Information leaflet Patient Information leaflet Finnish 13-05-2019
Summary of Product characteristics Summary of Product characteristics Finnish 13-05-2019
Public Assessment Report Public Assessment Report Finnish 03-10-2014
Patient Information leaflet Patient Information leaflet Swedish 13-05-2019
Summary of Product characteristics Summary of Product characteristics Swedish 13-05-2019
Public Assessment Report Public Assessment Report Swedish 03-10-2014
Patient Information leaflet Patient Information leaflet Norwegian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Norwegian 13-05-2019
Patient Information leaflet Patient Information leaflet Icelandic 13-05-2019
Summary of Product characteristics Summary of Product characteristics Icelandic 13-05-2019
Patient Information leaflet Patient Information leaflet Croatian 13-05-2019
Summary of Product characteristics Summary of Product characteristics Croatian 13-05-2019
Public Assessment Report Public Assessment Report Croatian 03-10-2014

Search alerts related to this product

Alerts Eryseng Parvo prašičev parvovirus, sev NADL-2 Porcine and Erysipelothrix rhusiopathiae

Eryseng Parvo prašičev parvovirus, sev NADL-2 Porcine and Erysipelothrix rhusiopathiae

View documents history

Documents history Documents history

Eryseng Parvo